

## CONTINUING MEDICAL EDUCATION

## Hepatobiliary Tumor Board - 3/15/2027 – 81291-78579

Date: March 15, 2027

Time: 4:00 PM-5:00 PM

UH Cleveland Medical Center

*Pierre Gholam, MD; Naemat Sandhu, MBBS*  
*University Hospitals Cleveland Medical Center, UHMG, University Hospitals*

### Educational Objectives

At the conclusion of this activity, the participant should be better able to:

- 1 Identify and apply the principles of quality and safety
- 2 Effectively discuss, diagnose, and prove management strategies of the highest quality of care to their patients with Hepatobiliary cancers
- 3 Design an appropriate plan of management of primary and metastatic Hepatobiliary cancers

### Accreditation and Credit Designation Statements

Case Western Reserve University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Case Western Reserve University School of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Disclosures:

All relevant financial relationships have been mitigated. This activity's planners and speaker(s) have made the following disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Pierre Gholam, MD	Course Director, Faculty	Advisor-Eisai, Inc. Advisor-Genentech, Inc. (Relationship has ended) Advisor-AstraZeneca Honoraria-exelixis (Relationship has ended) - 06/03/2026
Ashley Hepner, CNP	Other Planning Committee Member	Nothing to disclose - 06/01/2026
Naemat Sandhu, MBBS	Course Director, Faculty	Grant or research support-Ultragenyx Pharmaceutical Inc - 05/28/2026

PRESENTED BY:

SPONSORED BY:



Seth Sclair, MD	Other Planning Committee Member	Speakers Bureau-Mallinckrodt, Inc.   Honoraria-Guidepoint, Atheneum, Clearview,   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kezar Pharmaceuticals (Relationship has ended) - 06/10/2026
-----------------	---------------------------------	--